Skip to content

Transcranial Magnetic Stimulation in depression treatment

Transcranial Magnetic Stimulation in depression treatment - rTMS in depression

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35230
Enrollment
120
Registered
2010-06-08
Start date
2011-05-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression major depressive disorder

Interventions

rTMS on the right parietal cortex 2 Hz with an inter-impuls interval of 0,5 sec. at 110 % of motor threshold 15 sessions of 20 minutes during a period of three weeks

Sponsors

Sint Lucas Andreas Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: age from 18 yrs onward unipolar depressive disorder only the following medication is allowed: SSRI's, venlafaxine, mirtazapine, antihistamanics for sedation medication to be kept constant during the trial

Exclusion criteria

Exclusion criteria: bipolar disorder, dysthymic disorder suicidality Use of beta-blockers, other antidepressants or psychotropic medication, thyroid hormone, benzodiazepines, anti-epileptics history of epilepsy or epileptic abnormalities on EEG intracranial metal, pacemaker schizophrenia, addiction, mental handicap, not speaking Dutch lefthandedness

Design outcomes

Primary

MeasureTime frame
1. Percentage of change from baseline on the Hamilton Depression Rating Scale (HAMD, 17 items) 2. Percentage of patients with clinical response (= 50 % reduction in HAMD score) 3. Percentage of patients with partial clinical response (= 30 % reduction in HAMD score)

Secondary

MeasureTime frame
Emotion Recognition Task

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)